Adalimumab biosimilar Imraldi launched in European Union

Imraldi^TM is approved in the European Union (EU) for 13 of the same complex autoimmune conditions as its reference product and is now available in the UK via the NHS.

Imraldi is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis; enthesitis-related arthritis), axial spondyloarthritis (ankylosing spondylitis (AS) and axial spondyloarthritis with radiographic evidence of AS).

It is also approved for psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease and ulcerative uveitis.

“We are proud to be pioneering innovation in biosimilars to help transform the lives of people in the UK with chronic autoimmune conditions,”said Dan Cohen, regional director of Biogen UK, Ireland and Netherlands.

“With the addition of Imraldi to our anti-TNF biosimilar offering, we are increasing clinician choice and patient access in the UK to affordable treatments across disease areas,”he said.